Table 3.
Public health impact of Recombinant Zoster Vaccine and Varicella Vaccine Live over a lifetime horizon from the age of vaccination
| Number of cases if no vaccination | Cases avoideda | ||||
|---|---|---|---|---|---|
| RZV | VVL | ||||
| Low second-dose complianceb | Base casec | High second-dose complianceb | |||
| Number of persons vaccinatedd | – | 23,217,200 | 23,217,200 | 23,217,200 | 23,217,200 |
| HZ | 15,233,397 | 2,847,289 | 3,338,693 | 3,436,974 | 815,006 |
| PHN | 3,580,971 | 583,163 | 692,036 | 713,811 | 216,421 |
| Complications | 1,391,444 | 237,058 | 281,223 | 290,056 | 57,242 |
| Deaths | 1489 | 158 | 195 | 202 | 14 |
| Hospitalizations | 572,831 | 97,024 | 115,188 | 118,821 | 23,141 |
| Outpatient visits | 90,997,868 | 16,338,880 | 19,253,353 | 19,836,248 | 4,368,082 |
RZV Recombinant Zoster Vaccine, VVL Varicella Vaccine Live, HZ Herpes Zoste, PHN Postherpetic Neuralgia
aIn vaccinated persons compared with those not vaccinated over the lifetime of the respective cohorts
bLow, 70%; high, 100%
cBase-case assumptions: coverage, 40%; compliance with second-dose for RZV, 95%
dTotal cohort is 58,043,000